Objective:

To explore the potential of urine biomarkers, particularly DNA methylation, for diagnosing and monitoring non-muscle-invasive bladder cancer (NMIBC).

Approach:

• Current Challenges: Discusses the limitations of cystoscopy and urine cytology in diagnosing NMIBC, highlighting the need for more accurate, less invasive tests.
• Urine as a Biofluid: Explains the advantages of urine as a source for liquid biopsy biomarkers due to its contact with the urothelium.
• DNA Methylation Testing: Describes a PCR-based assay for detecting DNA methylation patterns, approved for clinical use, with a focus on its sensitivity and specificity.
• Follow-Up Testing: Details the role of DNA methylation testing as a complement to cystoscopy, enhancing patient management and reducing the frequency of invasive procedures.
• Implementation in Practice: Highlights the role of pathologists in the implementation of DNA methylation testing and the establishment of a certified laboratory for this purpose.

Key Findings:

• Cystoscopy and urine cytology have significant limitations in detecting NMIBC.
• DNA methylation testing shows a sensitivity of 74% and specificity of 84%, with higher rates for high-grade cancers (source needed).
• The test has a high negative predictive value (98%) for high-grade urothelial cancers, making it a useful 'rule-out' test.

Interpretation:

Limitations:

• Cystoscopy cannot be completely replaced by DNA methylation testing.
• Further studies are needed to assess the test's performance in diverse populations.

Conclusion:

Sources:

• Johnson&Johnson Editor's Series